{"id":"W2006528231","doi":"10.1378/chest.13-1579","title":"Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD","year":2014,"lang":"en","type":"article","venue":"CHEST Journal","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Placebo; COPD; Dry-powder inhaler; Inhaler; Bronchodilator; Adverse effect; Internal medicine; Clinical endpoint; Anesthesia; Asthma; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000303657,0.0002969169,0.001104615,0.000212695,0.0002951203,0.0003244086,0.0004028317,0.000531202,0.001043267],"category_scores_gemma":[0.0004416428,0.0001235638,0.0004261421,0.0001392457,0.0001734851,0.0002215082,0.0001832369,0.0008602962,0.0003003557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002967137,"about_ca_system_score_gemma":0.0002836904,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006009807,"about_ca_topic_score_gemma":0.001600072,"domain_scores_codex":[0.9998268,0.00005318239,0.00001532144,0.00002743585,0.00003079904,0.00004646133],"domain_scores_gemma":[0.9998758,0.0000279696,0.000017025,0.000007564553,0.000007458356,0.00006416497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1658053,0.006688516,0.01070896,0.0009796879,0.0006758702,0.001350003,0.000323666,0.001014867,0.2438182,0.0003137871,0.003440391,0.5648807],"study_design_scores_gemma":[0.07833447,0.3896145,0.3602796,0.0006947656,0.002456213,0.00833815,0.0008875507,0.006807008,0.1155358,0.0007846465,0.03605601,0.0002112185],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804361,0.01489312,0.0004619124,0.0003643536,0.0001446956,0.00009188383,0.0001272775,0.0001632743,0.00331749],"genre_scores_gemma":[0.9965349,0.001750193,0.0004766895,0.0001704975,0.00005296858,0.00003344882,0.0001049687,0.000008028635,0.0008682954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001104615,"threshold_uncertainty_score":0.003490031,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03055733209277989,"score_gpt":0.3138151470602951,"score_spread":0.2832578149675152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}